ANI Historical Balance Sheet

ANIP Stock

USD 61.66 0.05 0.08%

Trend analysis of ANI Pharmaceuticals balance sheet accounts such as Other Current Liab of 104.8 M, Total Current Liabilities of 152.8 M or Total Stockholder Equity of 454.4 M provides information on ANI Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of ANI Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using ANI Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining ANI Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether ANI Pharmaceuticals is a good buy for the upcoming year.

ANI Pharmaceuticals Inventory

116.76 Million

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ANI Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.

To learn how to invest in ANI Stock, please use our How to Invest in ANI Pharmaceuticals guide.

About ANI Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of ANI Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. ANI Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of ANI Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which ANI currently owns. An asset can also be divided into two categories, current and non-current.

ANI Pharmaceuticals Balance Sheet Chart

ANI Pharmaceuticals Balance Sheet is one of the main financial statements that report all assets, liabilities, and shareholders' equity for the current year. It provides a basis for different types of computing rates of return, such as return on equity (ROE) or return on asset (ROA), as well as shows how ANI Pharmaceuticals uses and utilizes its capital. It also shows what exactly a company owns and owes.

At this time, ANI Pharmaceuticals' Cash is relatively stable compared to the past year. As of 05/22/2024, Non Current Assets Total is likely to grow to about 404 M, while Common Stock is likely to drop 1,900.

Total Assets Other Current Liab Total Current Liabilities Total Stockholder Equity Non Current Assets Total Other Current Assets

Add Fundamental

Total Assets

Total assets refers to the total amount of ANI Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in ANI Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on ANI Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of ANI Pharmaceuticals are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Non Current Assets Total

The total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets.

Other Current Assets

Assets expected to be converted into cash, sold, or consumed either in one year or in the operating cycle, which are not included under standard current asset categories.

Most accounts from ANI Pharmaceuticals' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into ANI Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ANI Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.

To learn how to invest in ANI Stock, please use our How to Invest in ANI Pharmaceuticals guide.At this time, ANI Pharmaceuticals' Cash is relatively stable compared to the past year. As of 05/22/2024, Non Current Assets Total is likely to grow to about 404 M, while Common Stock is likely to drop 1,900.

	2021	2022	2023	2024 (projected)
Other Current Liabilities	63.6M	69.3M	99.8M	104.8M
Total Assets	771.6M	760.1M	904.4M	949.6M

Other Current Liab Total Assets

ANI Pharmaceuticals balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Other Current Assets	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Common Stock	Other Stockholder Equity	Short Long Term Debt Total	Short Term Debt	Current Deferred Revenue	Non Currrent Assets Other	Non Current Liabilities Total	Net Receivables	Net Tangible Assets
Total Assets		0.95	0.84	1.0	0.9	0.7	0.16	0.94	0.6	0.95	0.6	-0.48	0.93	0.53	1.0	0.96	0.95	-0.48	0.98	0.97	-0.19	0.09	0.55	0.92	0.97	0.09
Other Current Liab	0.95		0.87	0.95	0.88	0.61	0.06	0.97	0.58	0.87	0.58	-0.38	0.84	0.61	0.94	0.95	0.93	-0.38	0.94	0.89	-0.24	-0.09	0.45	0.85	0.96	0.14
Total Current Liabilities	0.84	0.87		0.83	0.86	0.65	0.16	0.81	0.43	0.82	0.43	-0.37	0.77	0.48	0.85	0.85	0.77	-0.37	0.79	0.82	-0.06	-0.17	0.32	0.65	0.83	-0.09
Total Stockholder Equity	1.0	0.95	0.83		0.88	0.64	0.15	0.94	0.66	0.92	0.66	-0.48	0.93	0.56	0.98	0.95	0.96	-0.48	0.99	0.96	-0.15	0.12	0.6	0.92	0.95	0.15
Property Plant And Equipment Net	0.9	0.88	0.86	0.88		0.83	0.26	0.83	0.32	0.95	0.32	-0.48	0.79	0.43	0.92	0.94	0.76	-0.48	0.85	0.91	-0.26	-0.22	0.24	0.81	0.91	-0.09
Net Debt	0.7	0.61	0.65	0.64	0.83		0.32	0.56	-0.13	0.88	-0.13	-0.46	0.61	0.16	0.74	0.74	0.44	-0.46	0.62	0.74	-0.26	-0.11	0.13	0.66	0.75	-0.46
Retained Earnings	0.16	0.06	0.16	0.15	0.26	0.32		-0.06	-0.04	0.27	-0.04	-0.89	0.3	-0.01	0.17	0.08	0.04	-0.89	0.18	0.26	0.4	0.33	0.29	0.02	0.09	-0.18
Accounts Payable	0.94	0.97	0.81	0.94	0.83	0.56	-0.06		0.62	0.83	0.62	-0.31	0.8	0.65	0.93	0.96	0.94	-0.31	0.93	0.89	-0.38	-0.12	0.44	0.89	0.96	0.22
Cash	0.6	0.58	0.43	0.66	0.32	-0.13	-0.04	0.62		0.34	1.0	-0.19	0.63	0.46	0.55	0.47	0.81	-0.19	0.65	0.52	0.1	0.35	0.65	0.52	0.47	0.61
Non Current Assets Total	0.95	0.87	0.82	0.92	0.95	0.88	0.27	0.83	0.34		0.34	-0.52	0.86	0.39	0.96	0.93	0.79	-0.52	0.9	0.95	-0.19	0.03	0.42	0.87	0.93	-0.16
Cash And Short Term Investments	0.6	0.58	0.43	0.66	0.32	-0.13	-0.04	0.62	1.0	0.34		-0.19	0.63	0.46	0.55	0.47	0.81	-0.19	0.65	0.52	0.1	0.35	0.65	0.52	0.47	0.61
Common Stock Total Equity	-0.48	-0.38	-0.37	-0.48	-0.48	-0.46	-0.89	-0.31	-0.19	-0.52	-0.19		-0.57	-0.33	-0.48	-0.41	-0.39	1.0	-0.53	-0.58	-0.21	-0.33	-0.52	-0.39	-0.43	0.01
Common Stock Shares Outstanding	0.93	0.84	0.77	0.93	0.79	0.61	0.3	0.8	0.63	0.86	0.63	-0.57		0.46	0.91	0.82	0.89	-0.57	0.93	0.92	0.09	0.35	0.7	0.84	0.85	0.11
Other Current Assets	0.53	0.61	0.48	0.56	0.43	0.16	-0.01	0.65	0.46	0.39	0.46	-0.33	0.46		0.5	0.56	0.6	-0.33	0.62	0.61	-0.38	-0.16	0.54	0.59	0.56	0.14
Total Liab	1.0	0.94	0.85	0.98	0.92	0.74	0.17	0.93	0.55	0.96	0.55	-0.48	0.91	0.5		0.97	0.92	-0.48	0.97	0.97	-0.22	0.06	0.51	0.92	0.98	0.05
Property Plant And Equipment Gross	0.96	0.95	0.85	0.95	0.94	0.74	0.08	0.96	0.47	0.93	0.47	-0.41	0.82	0.56	0.97		0.89	-0.41	0.94	0.94	-0.34	-0.16	0.36	0.91	0.98	0.08
Total Current Assets	0.95	0.93	0.77	0.96	0.76	0.44	0.04	0.94	0.81	0.79	0.81	-0.39	0.89	0.6	0.92	0.89		-0.39	0.96	0.89	-0.17	0.14	0.62	0.87	0.9	0.34
Common Stock	-0.48	-0.38	-0.37	-0.48	-0.48	-0.46	-0.89	-0.31	-0.19	-0.52	-0.19	1.0	-0.57	-0.33	-0.48	-0.41	-0.39		-0.53	-0.58	-0.21	-0.33	-0.52	-0.39	-0.43	0.01
Other Stockholder Equity	0.98	0.94	0.79	0.99	0.85	0.62	0.18	0.93	0.65	0.9	0.65	-0.53	0.93	0.62	0.97	0.94	0.96	-0.53		0.97	-0.17	0.14	0.64	0.93	0.95	0.18
Short Long Term Debt Total	0.97	0.89	0.82	0.96	0.91	0.74	0.26	0.89	0.52	0.95	0.52	-0.58	0.92	0.61	0.97	0.94	0.89	-0.58	0.97		-0.2	0.09	0.59	0.92	0.94	0.01
Short Term Debt	-0.19	-0.24	-0.06	-0.15	-0.26	-0.26	0.4	-0.38	0.1	-0.19	0.1	-0.21	0.09	-0.38	-0.22	-0.34	-0.17	-0.21	-0.17	-0.2		0.57	0.21	-0.38	-0.34	0.12
Current Deferred Revenue	0.09	-0.09	-0.17	0.12	-0.22	-0.11	0.33	-0.12	0.35	0.03	0.35	-0.33	0.35	-0.16	0.06	-0.16	0.14	-0.33	0.14	0.09	0.57		0.7	0.07	-0.06	0.08
Non Currrent Assets Other	0.55	0.45	0.32	0.6	0.24	0.13	0.29	0.44	0.65	0.42	0.65	-0.52	0.7	0.54	0.51	0.36	0.62	-0.52	0.64	0.59	0.21	0.7		0.54	0.44	0.09
Non Current Liabilities Total	0.92	0.85	0.65	0.92	0.81	0.66	0.02	0.89	0.52	0.87	0.52	-0.39	0.84	0.59	0.92	0.91	0.87	-0.39	0.93	0.92	-0.38	0.07	0.54		0.92	0.1
Net Receivables	0.97	0.96	0.83	0.95	0.91	0.75	0.09	0.96	0.47	0.93	0.47	-0.43	0.85	0.56	0.98	0.98	0.9	-0.43	0.95	0.94	-0.34	-0.06	0.44	0.92		0.06
Net Tangible Assets	0.09	0.14	-0.09	0.15	-0.09	-0.46	-0.18	0.22	0.61	-0.16	0.61	0.01	0.11	0.14	0.05	0.08	0.34	0.01	0.18	0.01	0.12	0.08	0.09	0.1	0.06

Click cells to compare fundamentals

ANI Pharmaceuticals Account Relationship Matchups

ANI Pharmaceuticals balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	456.8M	461.2M	771.6M	760.1M	904.4M	949.6M
Other Current Liab	36.7M	54.0M	63.6M	69.3M	99.8M	104.8M
Total Current Liabilities	61.7M	78.6M	87.5M	99.4M	145.5M	152.8M
Total Stockholder Equity	212.8M	195.7M	358.7M	338.5M	432.7M	454.4M
Property Plant And Equipment Net	40.6M	41.3M	52.7M	43.2M	44.6M	46.8M
Net Debt	123.4M	177.8M	187.1M	238.3M	94.2M	98.9M
Retained Earnings	17.6M	(5.0M)	(47.8M)	(97.3M)	(80.1M)	(84.1M)
Accounts Payable	14.6M	11.3M	23.0M	29.3M	36.7M	38.5M
Cash	62.3M	7.9M	100.3M	48.2M	221.1M	232.2M
Non Current Assets Total	269.1M	290.9M	449.8M	415.8M	384.8M	404.0M
Cash And Short Term Investments	62.3M	7.9M	100.3M	48.2M	221.1M	232.2M
Common Stock Shares Outstanding	12.0M	12.0M	12.6M	16.3M	18.2M	19.1M
Liabilities And Stockholders Equity	456.8M	461.2M	771.6M	760.1M	904.4M	949.6M
Other Current Assets	5.1M	5.9M	11.3M	8.4M	25.2M	26.5M
Total Liab	244.0M	265.5M	412.9M	421.5M	471.7M	495.3M
Property Plant And Equipment Gross	40.6M	41.3M	75.6M	76.0M	77.5M	81.4M
Total Current Assets	187.7M	170.3M	321.8M	344.3M	519.6M	545.6M
Other Stockholder Equity	200.1M	212.1M	384.7M	398.8M	479.2M	503.1M
Accumulated Other Comprehensive Income	(4.9M)	(11.4M)	(3.1M)	12.2M	8.9M	9.3M
Short Long Term Debt Total	185.7M	185.7M	287.4M	286.5M	315.3M	331.1M
Short Term Debt	115.7M	9.9M	13.2M	850K	977.5K	928.6K
Current Deferred Revenue	451K	80K	87K	8.2M	9.4M	9.9M
Non Currrent Assets Other	1.2M	802K	2.2M	2.6M	6.1M	6.4M
Non Current Liabilities Total	182.3M	186.9M	325.3M	322.1M	326.2M	342.5M
Net Receivables	72.1M	95.8M	128.5M	165.4M	162.1M	170.2M
Net Tangible Assets	28.8M	3.6M	36.7M	58.7M	52.8M	55.5M
Other Assets	44.6M	57.5M	75.1M	92.7M	106.6M	112.0M
Long Term Debt	175.8M	172.4M	286.5M	285.7M	284.8M	149.2M
Retained Earnings Total Equity	17.6M	(5.0M)	(47.8M)	(97.3M)	(111.9M)	(117.5M)
Inventory	48.2M	60.8M	81.7M	105.4M	111.2M	116.8M
Deferred Long Term Liab	1.5M	800K	500K	600K	690K	458.1K
Intangible Assets	180.4M	188.5M	294.1M	251.6M	209.0M	156.5M
Property Plant Equipment	40.6M	41.3M	52.7M	43.2M	49.7M	52.2M
Capital Surpluse	200.8M	214.4M	387.8M	403.9M	464.5M	237.5M
Other Liab	7K	201K	31.0M	35.1M	40.3M	42.3M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether ANI Pharmaceuticals is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if ANI Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Ani Pharmaceuticals Stock. Highlighted below are key reports to facilitate an investment decision about Ani Pharmaceuticals Stock:

How To Invest In ANI

Details

Is ANI Stock a good investment?

Details

What is ANI Pharmaceuticals' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

To learn how to invest in ANI Stock, please use our How to Invest in ANI Pharmaceuticals guide.

You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.

Complementary Tools for ANI Stock analysis

When running ANI Pharmaceuticals' price analysis, check to measure ANI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ANI Pharmaceuticals is operating at the current time. Most of ANI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ANI Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ANI Pharmaceuticals' price. Additionally, you may evaluate how the addition of ANI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

	Technical Analysis Check basic technical indicators and analysis based on most latest market data
	Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges
	Equity Valuation Check real value of public entities based on technical and fundamental data
	Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years
	Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets
	Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
	Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals

Is ANI Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ANI Pharmaceuticals. If investors know ANI will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ANI Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

13.824

Earnings Share

1.61

Revenue Per Share

27.705

Quarterly Revenue Growth

0.287

Return On Assets

0.0391

The market value of ANI Pharmaceuticals is measured differently than its book value, which is the value of ANI that is recorded on the company's balance sheet. Investors also form their own opinion of ANI Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is ANI Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ANI Pharmaceuticals' market value can be influenced by many factors that don't directly affect ANI Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between ANI Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if ANI Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ANI Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

ANI Historical Balance Sheet

ANI Pharmaceuticals Inventory

116.76 Million

About ANI Balance Sheet Analysis

ANI Pharmaceuticals Balance Sheet Chart

Total Assets

Total Current Liabilities

Total Stockholder Equity

Non Current Assets Total

Other Current Assets

ANI Pharmaceuticals balance sheet Correlations

ANI Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

ANI Pharmaceuticals balance sheet Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for ANI Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Total Liab	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Cash
Common Stock	+ 1.0	Common Stock Total Equity
Other Stockholder Equity	+ 0.99	Total Stockholder Equity
Other Stockholder Equity	+ 0.98	Total Assets

Common Stock	- 0.89	Retained Earnings
Common Stock Total Equity	- 0.89	Retained Earnings
Short Long Term Debt Total	- 0.58	Common Stock
Short Long Term Debt Total	- 0.58	Common Stock Total Equity
Common Stock	- 0.57	Common Stock Shares Outstanding
Common Stock Shares Outstanding	- 0.57	Common Stock Total Equity